CeriBell (CBLL) Stock Price, News & Analysis

Company Overview

CeriBell, Inc. is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools. The system is intended for use in settings such as intensive care units and emergency departments, where rapid neurological assessment can support clinical decision-making.

Founded in 2015 and headquartered in Sunnyvale, California, CeriBell markets its products primarily to hospitals and healthcare providers. Its offerings are designed to make EEG testing more accessible outside traditional neurology departments by reducing the time and technical resources typically required to initiate monitoring.

Key Stats

• Today's Range: $27.00 to $28.19
• 50-Day Range: $23.15 to $27.68
• 52-Week Range: $10.85 to $28.19
• Volume: 235,573 shs
• Average Volume: 360,249 shs
• Market Capitalization: $1.06 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.00
• Consensus Rating: Moderate Buy

CeriBell Stock Analysis - MarketRank™

CeriBell scored higher than 24% of companies evaluated by MarketBeat, and ranked 794th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CeriBell has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for CeriBell is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

CeriBell has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CeriBell are expected to grow in the coming year, from ($1.96) to ($1.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CeriBell is -15.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CeriBell is -15.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CeriBell has a P/B Ratio of 6.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.83% of the float of CeriBell has been sold short.

Short Interest Ratio / Days to Cover

CeriBell has a short interest ratio ("days to cover") of 4.79.

Change versus previous month

Short interest in CeriBell has recently increased by 6.85%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CeriBell does not currently pay a dividend.

Dividend Growth

CeriBell does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.47

News Sentiment

CeriBell has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for CeriBell this week, compared to 5 articles on an average week.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CeriBell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,312,995.00 in company stock.

Percentage Held by Insiders

17.70% of the stock of CeriBell is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

CeriBell has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/29/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CBLL
• Previous Symbol: NASDAQ:CBLL
• CIK: 1861107
• Web: www.ceribell.com
• Phone: (800) 436-0826
• Fax: N/A
• Employees: 300
• Year Founded: 2014

Price Target and Rating

• Average Price Target for CeriBell: $27.00
• High Price Target: $33.00
• Low Price Target: $17.00
• Potential Upside/Downside: -2.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.41 million
• Net Margins: -64.73%
• Pretax Margin: -64.73%
• Return on Equity: -44.85%
• Return on Assets: -35.69%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 9.18
• Quick Ratio: 8.79

Sales & Book Value

• Annual Sales: $89.06 million
• Price / Sales: 11.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.19 per share
• Price / Book: 6.64

Miscellaneous

• Outstanding Shares: 38,380,000
• Free Float: 31,585,000
• Market Cap: $1.07 billion
• Optionable: Optionable
• Beta: 0.94